Waleed Abdulaziz Altwaijri, Tuline A Almazyad, Yara Ahmad Abuzaid, Jumanah Nasser Alkhater, Dalal M Ashmawi, Ghadah Khalid Alnami, Lujain A Almazyad, Sadeem Khalid Alnami, Rawan Ahmad Abuzaid, Lujeen Nasser Alkhater
Parental awareness of headaches among elementary school-aged children in Riyadh, Saudi Arabia: A cross-sectional studyz
Journal of family medicine and primary care
use antipsychotic medication prevention psychotic disorders controversial longchain omega3 omega3 polyunsaturated fatty acids pufas may beneficial range psychiatric conditions including schizophrenia given omega3 pufas generally beneficial health without clinically relevant adverse effects preventive use psychosis merits investigationto determine whether omega3 pufas reduce rate progression firstepisode psychotic disorder adolescents young adults aged 13 25 years subthreshold psychosisrandomized doubleblind placebocontrolled trial conducted 2004 2007psychosis detection unit large public hospital vienna austriaeightyone individuals ultrahigh risk psychotic disordera 12week intervention period 12gd omega3 pufa placebo followed 40week monitoring period total study period 12 monthsthe primary outcome measure transition psychotic disorder secondary outcomes included symptomatic functional changes ratio omega6 omega3 fatty acids erythrocytes used index pretreatment vs posttreatment fatty acid compositionseventysix 81 participants 938 completed intervention studys end 12 months 2 41 individuals 49 omega3 group 11 40 275 placebo group transitioned psychotic disorder p 007 difference groups cumulative risk progression fullthreshold psychosis 226 95 confidence interval 48404 omega3 polyunsaturated fatty acids also significantly reduced positive symptoms p 01 negative symptoms p 02 general symptoms p 01 improved functioning p 002 compared placebo incidence adverse effects differ treatment groupslongchain omega3 pufas reduce risk progression psychotic disorder may offer safe efficacious strategy indicated prevention young people subthreshold psychotic states trial registration clinicaltrialsgov identifier nct00396643